The Role of Sclerostin in Bone Diseases
Sclerostin has been identified as an important regulator of bone homeostasis through inhibition of the canonical Wnt-signaling pathway, and it is involved in the pathogenesis of many different skeletal diseases. Many studies have been published in the last few years regarding sclerostin's origi...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2022-02, Vol.11 (3), p.806 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 806 |
| container_title | Journal of clinical medicine |
| container_volume | 11 |
| creator | Vasiliadis, Elias S Evangelopoulos, Dimitrios-Stergios Kaspiris, Angelos Benetos, Ioannis S Vlachos, Christos Pneumaticos, Spyros G |
| description | Sclerostin has been identified as an important regulator of bone homeostasis through inhibition of the canonical Wnt-signaling pathway, and it is involved in the pathogenesis of many different skeletal diseases. Many studies have been published in the last few years regarding sclerostin's origin, regulation, and mechanism of action. The ongoing research emphasizes the potential therapeutic implications of sclerostin in many pathological conditions with or without skeletal involvement. Antisclerostin antibodies have recently been approved for the treatment of osteoporosis, and several animal studies and clinical trials are currently under way to evaluate the effectiveness of antisclerostin antibodies in the treatment of other than osteoporosis skeletal disorders and cancer with promising results. Understanding the exact role of sclerostin may lead to new therapeutic approaches for the treatment of skeletal disorders. |
| doi_str_mv | 10.3390/jcm11030806 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8836457</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2627672985</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-aca55f28239122336c0fa0293a04f6914be2e976da3d970106f97f08dfecbe483</originalsourceid><addsrcrecordid>eNpdkU1LAzEQhoMottSevMuCBwVZnSS7-bgIWj-hIGg9hzQ7sVu2m7ppBf-9W1pLdRiYgXl4eWeGkGMKl5xruJq6GaXAQYHYI10GUqbAFd_f6TukH-MU2lAqY1Qekg7PqQCWqy45G00weQ0VJsEnb67CJsRFWSdt3oYak7syoo0Yj8iBt1XE_qb2yPvD_WjwlA5fHp8HN8PUZaAXqXU2zz1TjGvKGOfCgbfANLeQeaFpNkaGWorC8kJLoCC8lh5U4dGNMVO8R67XuvPleIaFw3rR2MrMm3Jmm28TbGn-TupyYj7Cl1GKiyyXrcD5RqAJn0uMCzMro8OqsjWGZTRMMA2CUbVCT_-h07Bs6na9FSWFZFrlLXWxplx7mtig35qhYFY_MDs_aOmTXf9b9vfi_AdKUX9f</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627672985</pqid></control><display><type>article</type><title>The Role of Sclerostin in Bone Diseases</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Vasiliadis, Elias S ; Evangelopoulos, Dimitrios-Stergios ; Kaspiris, Angelos ; Benetos, Ioannis S ; Vlachos, Christos ; Pneumaticos, Spyros G</creator><creatorcontrib>Vasiliadis, Elias S ; Evangelopoulos, Dimitrios-Stergios ; Kaspiris, Angelos ; Benetos, Ioannis S ; Vlachos, Christos ; Pneumaticos, Spyros G</creatorcontrib><description>Sclerostin has been identified as an important regulator of bone homeostasis through inhibition of the canonical Wnt-signaling pathway, and it is involved in the pathogenesis of many different skeletal diseases. Many studies have been published in the last few years regarding sclerostin's origin, regulation, and mechanism of action. The ongoing research emphasizes the potential therapeutic implications of sclerostin in many pathological conditions with or without skeletal involvement. Antisclerostin antibodies have recently been approved for the treatment of osteoporosis, and several animal studies and clinical trials are currently under way to evaluate the effectiveness of antisclerostin antibodies in the treatment of other than osteoporosis skeletal disorders and cancer with promising results. Understanding the exact role of sclerostin may lead to new therapeutic approaches for the treatment of skeletal disorders.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm11030806</identifier><identifier>PMID: 35160258</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antibodies ; Apoptosis ; Clinical medicine ; Disease ; Estrogens ; Gene expression ; Growth factors ; Kinases ; Ligands ; Osteoporosis ; Pathogenesis ; Review ; Womens health</subject><ispartof>Journal of clinical medicine, 2022-02, Vol.11 (3), p.806</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-aca55f28239122336c0fa0293a04f6914be2e976da3d970106f97f08dfecbe483</citedby><cites>FETCH-LOGICAL-c409t-aca55f28239122336c0fa0293a04f6914be2e976da3d970106f97f08dfecbe483</cites><orcidid>0000-0003-2428-5250 ; 0000-0003-3265-5522</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836457/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836457/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27913,27914,53780,53782</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35160258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vasiliadis, Elias S</creatorcontrib><creatorcontrib>Evangelopoulos, Dimitrios-Stergios</creatorcontrib><creatorcontrib>Kaspiris, Angelos</creatorcontrib><creatorcontrib>Benetos, Ioannis S</creatorcontrib><creatorcontrib>Vlachos, Christos</creatorcontrib><creatorcontrib>Pneumaticos, Spyros G</creatorcontrib><title>The Role of Sclerostin in Bone Diseases</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Sclerostin has been identified as an important regulator of bone homeostasis through inhibition of the canonical Wnt-signaling pathway, and it is involved in the pathogenesis of many different skeletal diseases. Many studies have been published in the last few years regarding sclerostin's origin, regulation, and mechanism of action. The ongoing research emphasizes the potential therapeutic implications of sclerostin in many pathological conditions with or without skeletal involvement. Antisclerostin antibodies have recently been approved for the treatment of osteoporosis, and several animal studies and clinical trials are currently under way to evaluate the effectiveness of antisclerostin antibodies in the treatment of other than osteoporosis skeletal disorders and cancer with promising results. Understanding the exact role of sclerostin may lead to new therapeutic approaches for the treatment of skeletal disorders.</description><subject>Antibodies</subject><subject>Apoptosis</subject><subject>Clinical medicine</subject><subject>Disease</subject><subject>Estrogens</subject><subject>Gene expression</subject><subject>Growth factors</subject><subject>Kinases</subject><subject>Ligands</subject><subject>Osteoporosis</subject><subject>Pathogenesis</subject><subject>Review</subject><subject>Womens health</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkU1LAzEQhoMottSevMuCBwVZnSS7-bgIWj-hIGg9hzQ7sVu2m7ppBf-9W1pLdRiYgXl4eWeGkGMKl5xruJq6GaXAQYHYI10GUqbAFd_f6TukH-MU2lAqY1Qekg7PqQCWqy45G00weQ0VJsEnb67CJsRFWSdt3oYak7syoo0Yj8iBt1XE_qb2yPvD_WjwlA5fHp8HN8PUZaAXqXU2zz1TjGvKGOfCgbfANLeQeaFpNkaGWorC8kJLoCC8lh5U4dGNMVO8R67XuvPleIaFw3rR2MrMm3Jmm28TbGn-TupyYj7Cl1GKiyyXrcD5RqAJn0uMCzMro8OqsjWGZTRMMA2CUbVCT_-h07Bs6na9FSWFZFrlLXWxplx7mtig35qhYFY_MDs_aOmTXf9b9vfi_AdKUX9f</recordid><startdate>20220202</startdate><enddate>20220202</enddate><creator>Vasiliadis, Elias S</creator><creator>Evangelopoulos, Dimitrios-Stergios</creator><creator>Kaspiris, Angelos</creator><creator>Benetos, Ioannis S</creator><creator>Vlachos, Christos</creator><creator>Pneumaticos, Spyros G</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2428-5250</orcidid><orcidid>https://orcid.org/0000-0003-3265-5522</orcidid></search><sort><creationdate>20220202</creationdate><title>The Role of Sclerostin in Bone Diseases</title><author>Vasiliadis, Elias S ; Evangelopoulos, Dimitrios-Stergios ; Kaspiris, Angelos ; Benetos, Ioannis S ; Vlachos, Christos ; Pneumaticos, Spyros G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-aca55f28239122336c0fa0293a04f6914be2e976da3d970106f97f08dfecbe483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies</topic><topic>Apoptosis</topic><topic>Clinical medicine</topic><topic>Disease</topic><topic>Estrogens</topic><topic>Gene expression</topic><topic>Growth factors</topic><topic>Kinases</topic><topic>Ligands</topic><topic>Osteoporosis</topic><topic>Pathogenesis</topic><topic>Review</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vasiliadis, Elias S</creatorcontrib><creatorcontrib>Evangelopoulos, Dimitrios-Stergios</creatorcontrib><creatorcontrib>Kaspiris, Angelos</creatorcontrib><creatorcontrib>Benetos, Ioannis S</creatorcontrib><creatorcontrib>Vlachos, Christos</creatorcontrib><creatorcontrib>Pneumaticos, Spyros G</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vasiliadis, Elias S</au><au>Evangelopoulos, Dimitrios-Stergios</au><au>Kaspiris, Angelos</au><au>Benetos, Ioannis S</au><au>Vlachos, Christos</au><au>Pneumaticos, Spyros G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Role of Sclerostin in Bone Diseases</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2022-02-02</date><risdate>2022</risdate><volume>11</volume><issue>3</issue><spage>806</spage><pages>806-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Sclerostin has been identified as an important regulator of bone homeostasis through inhibition of the canonical Wnt-signaling pathway, and it is involved in the pathogenesis of many different skeletal diseases. Many studies have been published in the last few years regarding sclerostin's origin, regulation, and mechanism of action. The ongoing research emphasizes the potential therapeutic implications of sclerostin in many pathological conditions with or without skeletal involvement. Antisclerostin antibodies have recently been approved for the treatment of osteoporosis, and several animal studies and clinical trials are currently under way to evaluate the effectiveness of antisclerostin antibodies in the treatment of other than osteoporosis skeletal disorders and cancer with promising results. Understanding the exact role of sclerostin may lead to new therapeutic approaches for the treatment of skeletal disorders.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35160258</pmid><doi>10.3390/jcm11030806</doi><orcidid>https://orcid.org/0000-0003-2428-5250</orcidid><orcidid>https://orcid.org/0000-0003-3265-5522</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2022-02, Vol.11 (3), p.806 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8836457 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Antibodies Apoptosis Clinical medicine Disease Estrogens Gene expression Growth factors Kinases Ligands Osteoporosis Pathogenesis Review Womens health |
| title | The Role of Sclerostin in Bone Diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T08%3A37%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Role%20of%20Sclerostin%20in%20Bone%20Diseases&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Vasiliadis,%20Elias%20S&rft.date=2022-02-02&rft.volume=11&rft.issue=3&rft.spage=806&rft.pages=806-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm11030806&rft_dat=%3Cproquest_pubme%3E2627672985%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627672985&rft_id=info:pmid/35160258&rfr_iscdi=true |